| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11095-007-9300-X |
| P698 | PubMed publication ID | 17457659 |
| P2093 | author name string | Ying Huang | |
| Wolfgang Sadée | |||
| Hojin Moon | |||
| Ruqing Liu | |||
| Zunyan Dai | |||
| Paul E Blower | |||
| Anh-Nhan Pham | |||
| Jialong Fang | |||
| P2860 | cites work | Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation | Q24564127 |
| Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance | Q28267606 | ||
| DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90 | Q28376524 | ||
| New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
| Biochemistry of multidrug resistance mediated by the multidrug transporter | Q29616476 | ||
| A gene expression database for the molecular pharmacology of cancer | Q29619242 | ||
| Synthesis and biological activities of novel 17-aminogeldanamycin derivatives | Q31115482 | ||
| Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays | Q34314238 | ||
| Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach | Q35101874 | ||
| Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective | Q35551871 | ||
| Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays | Q35620969 | ||
| Critical update and emerging trends in epidermal growth factor receptor targeting in cancer | Q36064490 | ||
| Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells | Q36260372 | ||
| Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 | ||
| Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/glutamate transport system xc-. | Q40157825 | ||
| Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin | Q40345142 | ||
| Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance | Q40384692 | ||
| Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. | Q40449494 | ||
| Interaction of imatinib mesilate with human P-glycoprotein | Q40634392 | ||
| Function and regulation of the human multidrug resistance gene | Q40867756 | ||
| An information-intensive approach to the molecular pharmacology of cancer. | Q41134023 | ||
| Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression | Q41551647 | ||
| The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets | Q41640356 | ||
| 17AAG: low target binding affinity and potent cell activity--finding an explanation | Q44317123 | ||
| Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1. | Q45236964 | ||
| Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models | Q46446464 | ||
| Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin | Q46450365 | ||
| Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin | Q46803761 | ||
| Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. | Q47988213 | ||
| Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. | Q54205689 | ||
| P-glycoprotein substrates and antagonists cluster into two distinct groups | Q63247812 | ||
| In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein | Q73692524 | ||
| Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of P-glycoprotein | Q74342599 | ||
| Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer | Q81414742 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1702-1712 | |
| P577 | publication date | 2007-04-25 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Chemogenomic analysis identifies geldanamycins as substrates and inhibitors of ABCB1. | |
| P478 | volume | 24 |
| Q34754007 | A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields |
| Q42932395 | Ascorbic acid inhibition of Candida albicans Hsp90-mediated morphogenesis occurs via the transcriptional regulator Upc2. |
| Q38769105 | Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. |
| Q37226339 | P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response |
| Q46114458 | Pharmacogenomics approach reveals MRP1 (ABCC1)-mediated resistance to geldanamycins |
| Q56985288 | Prioritization of Transporter-Drug Relationships From Drug Sensitivity Screens |
Search more.